Caimi G, Catania A, Frazzetta F, Capobianco D, Sarno A
Jpn Heart J. 1983 Sep;24(5):723-9. doi: 10.1536/ihj.24.723.
We examined the haemorheological determinants in a group of 52 hypertensives (diastolic basal pressure greater than 100 mmHg) subdivided in relation to the clinical stage (I and II or III according to the WHO classification) and in a group of 50 normal controls, matched for age and sex. From this study, it is evident that only plasma viscosity, fibrinogen and the fibrinogen/albumin ratio are able to distinguish normals from hypertensives. It is also clear that the clinical stage does not influence the haemorheological findings. These haemorheological factors were also measured in 3 groups of hypertensives treated with either timolol (20 mg/day), metoprolol (200 mg/day) or oxprenolol (160 mg/day). After a basal evaluation, measurements were performed, at regular intervals of 10 days, for a period of 30 days. The only significant changes were obtained using timolol; metoprolol and oxprenolol, did not affect these haemorheological parameters.
我们研究了52名高血压患者(舒张压基础值大于100 mmHg)的血液流变学决定因素,这些患者根据临床分期(按照WHO分类为I期和II期或III期)进行了细分,并与50名年龄和性别相匹配的正常对照者进行了比较。从这项研究中可以明显看出,只有血浆粘度、纤维蛋白原和纤维蛋白原/白蛋白比值能够区分正常人和高血压患者。同样清楚的是,临床分期并不影响血液流变学结果。我们还对3组分别用噻吗洛尔(20 mg/天)、美托洛尔(200 mg/天)或氧烯洛尔(160 mg/天)治疗的高血压患者进行了这些血液流变学因素的测量。在进行基础评估后,每隔10天进行一次测量,为期30天。使用噻吗洛尔获得了唯一显著的变化;美托洛尔和氧烯洛尔并未影响这些血液流变学参数。